AI Article Synopsis
Article Abstract
Objective: The classical allergic march model posits that atopy begins in infancy with atopic dermatitis and progresses to asthma and allergic rhinitis in a subset of individuals. The growing prevalence and severity of allergic diseases have prompted renewed interest in refining this model. This review outlines epidemiologic evidence for the existence of allergic march trajectories (distinct paths of atopy development in individuals); reviews the roles that genetics, environment, and disease endotypes play in determining trajectory outcomes; and discusses the clinical utility of the trajectory model.
Data Sources: PubMed search of English-language articles and reviews without date limits pertaining to the epidemiology, genetics, and immunologic mechanisms of allergic march trajectories and disease endotypes.
Study Selections: Studies and reviews were selected based on their high quality and direct relevance to the review topic.
Results: Recent work in the field has revealed that immunoglobulin E-mediated food allergy and eosinophilic esophagitis are components of the allergic march. Furthermore, the field is acknowledging that variability exists in the number and sequence of allergic manifestations that individuals develop. These allergic march pathways, or trajectories, are influenced by genetic, environmental, and psychosocial factors that are incompletely understood.
Conclusion: Continued elucidation of the landscape and origins of allergic march trajectories will inform efforts to personalize allergic disease prevention, diagnosis, and treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418995 | PMC |
| http://dx.doi.org/10.1016/j.anai.2021.04.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular complications in vascular connective tissue disorders after COVID-19 infection and vaccination.
PLoS One
December 2024
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Background: COVID-19 infection and vaccination have been reported to confer an elevated risk for cardiovascular events (CVE). We sought to determine whether individuals with an underlying vascular connective tissue disorder including Marfan syndrome (MFS), Loeys-Dietz syndrome (LDS), or vascular Ehlers Danlos syndrome (vEDS) are at increased risk for cardiac events after COVID-19 infection or vaccination.
Methods: 325 respondents self-reported data through a cross-sectional, web-based survey available from 22 November 2021, through 15 March 2022 regarding COVID-19 illness and vaccinations, the occurrence of any CVE, and adverse events following vaccination.
Efficacy and safety of 128 slice CT low-dose scanning technique combined with low-density contrast agent in computed tomography angiography of diabetic foot and lower limb.
Am J Transl Res
November 2024
Department of Medical Imaging, Shaanxi Kangfu Hospital No. 52, Electronic 2nd Road, Electronic City, Xi'an 710065, Shaanxi, China.
Objective: To evaluate the efficacy and safety of 128 slice CT low-dose scanning technology combined with low-density contrast agent in lower extremity computed tomography angiography (CTA) for patients with diabetic foot.
Methods: A retrospective study was conducted on 342 patients with diabetic foot admitted to Shaanxi Kangfu Hospital from March 2021 to May 2023. Of these, 181 received 128 slice CT low-dose scanning technology combined with low-density contrast medium for lower extremity CTA examination (research group), and 161 patients underwent conventional dose contrast medium for CTA examination (control group).
Serum GFAP and UCH-L1 for the identification of clinically important traumatic brain injury in children in France: a diagnostic accuracy substudy.
Lancet Child Adolesc Health
January 2025
Biochemistry and Molecular Genetics Department, CHU Clermont-Ferrand, Clermont-Ferrand, France; Faculty of Medicine, CNRS 6293, INSERM 1103, iGReD, Université Clermont Auvergne, Clermont-Ferrand, France. Electronic address:
Background: Many children with mild traumatic brain injury (mTBI), defined by a Glasgow Coma Scale (GCS) score between 13 and 15, undergo hospitalisation or cranial CT (CCT) scans despite the absence of clinically important traumatic brain injury (ciTBI; ie, hospitalisation >2 days associated with intracranial lesions on CCT, neurosurgical intervention, intensive care admission, or death). Clinical algorithms have reduced CCT scans and hospitalisations by 10%. We aimed to established age-appropriate reference values for GFAP and UCH-L1 and evaluate their diagnostic test performance in identifying ciTBI in children.
View Article and Find Full Text PDFDupilumab and atopic march; Reduction of incident allergic events or Clinical control?
Rev Alerg Mex
September 2024
Group of Clinical and Experimental Allergy, Hospital "Alma Mater de Antioquia", University of Antioquia (Medellín, Colombia).
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J).
Curr Med Res Opin
December 2024
Department of Dermatology, Dokkyo Medical University, Tochigi, Japan.
Article Synopsis
- The study aimed to assess the effectiveness and safety of lebrikizumab when combined with topical corticosteroids in Japanese patients aged 12 and older with moderate-to-severe atopic dermatitis (AD).
- Conducted over 16 weeks, the Phase 3 trial involved 286 participants who were randomly assigned to receive either lebrikizumab (administered every 2 or 4 weeks) or a placebo, with results showing significantly higher rates of improvement in skin condition among those receiving lebrikizumab.
- The treatment was found to have a good safety profile, with serious adverse events being rare, though some mild to moderate side effects were more common in the lebrikizumab groups compared to the placebo
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!